Navigation Links
Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Date:12/10/2010

SAN ANTONIO Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic in Berlin, Germany.

The GeparQuinto study was conducted at 85 centers throughout Germany and includes 2,500 patients, 550 of whom have HER2-neu-overexpressing breast cancer. This is the largest prospective patient cohort of chemo-targeted neoadjuvant therapy worldwide.

All patients received four cycles of 90 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every three weeks, followed by four cycles of 100 mg/m2 docetaxel. They were randomly assigned to also receive concomitant 6 mg/kg trastuzumab every three weeks or 1,250 mg lapatinib per day throughout all cycles.

At baseline, patient characteristics were similar between the two groups, with both groups presenting a clinical median tumor size of 40 mm. The researchers also reported a similar number of patients in each group with T4a-c or T4d disease, bilateral, multifocal or multicentric disease, and estrogen receptor-negative and progesterone receptor-negative disease.

The last of the patients are currently undergoing surgery, and Untch will present histological and surgical outcome results for these patients at the symposium.

"After assessing response to neoadjuvant chemo-targeted therapy in patients with HER2 overexpressing tumors, we are following the patients from this study to see whether pathologic complete response at surgery is correlated to the outcome of the patients," he said.

<
'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
2. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
3. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. First X-ray lasers early success brings approval for next-phase facility
6. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
7. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
8. First phase of pan-tropical forest mapping debuting at COP15
9. NIH funds new phase of high school-university research partnership
10. Scientists seek new emphases in Arctic climate change research
11. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... the popular attention of both children and aquarium hobbyists ... as dehydrated eggs, these tiny brine shrimp readily hatch, ... of salt water. , Physicists, though, are interested ... vertically migrate in large groups in response to changing ... and retreating deeper during the day. , Two researchers ...
(Date:9/30/2014)... Medicine reports positive results of a phase 1 ... of lung cancer marked by rearrangement of the gene ... advanced non-small cell lung cancer testing positive for ROS1 ... 3 complete responses and 33 partial responses. Median progression-free ... to resume its growth after being slowed by treatment ...
(Date:9/30/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new ... sensitive to chemotherapeutic drugs. They have also pinpointed ... target for anti-tumor agents. , Researchers led ... Sieber of the Technische Universitt Mnchen have identified ... new weapon in the fight against malignant tumors. ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2
... engine is far from easy. Due to the turbulent ... are the same. Furthermore, the measurements are difficult to ... into the cylinder causes an extra source of turbulence. ... an engine adapted for this purpose. Laser Induced ...
... that a protein known as PEPT2 protects the brains ... toxic compound present in lead poisoning and in a ... neurological complications. Scientists at the University of ... 5-aminolevulinic acid (5-ALA), mice without the PEPT2 protein died ...
... United States Department of Agriculture (USDA) recently examined the ... production of packaged produce. The study, published in the ... learn more about how industry practices affect quality and ... Food Technologist at the United States Department of Agriculture,s ...
Cached Biology News:Fresh-cut produce washing practices can minimize food-borne illness risks 2
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , ... , a leader in synthetic biology, and ... drug manufacturer by volume in the U.S., today ... Collaboration (ECC) for a target active pharmaceutical ingredient ... goal of the collaboration is to develop a ...
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider ... technology, today announced its participation in the 2014 Big ... Data solutions provide semantic linkage and meaning to Big ... and manage diverse data. Ben Szekely, vice president and ... a “life sciences data lake” and an approach for ...
(Date:10/1/2014)... 1, 2014  Discovery Laboratories, Inc. (Nasdaq: DSCO) ... a Phase II Small Business Innovation Research Grant ... the National Institute of Allergy and Infectious Diseases ... to support the development of the Company,s aerosolized ... to mitigate acute and chronic/late-phase radiation-induced lung injury. ...
Breaking Biology Technology:Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... 10 Beckman Coulter, Inc. (NYSE: BEC ... that simplify, automate, and innovate complex biomedical testing, will ... 2009, beginning at 10:00 a.m. (ET). The webcast ... www.beckmancoulter.com . To access the webcast select ...
... for the Treatment of EpilepsyBRANFORD, Conn., April 10 ... serious neurological and psychiatric disorders, today announced the close ... comes on the heels of the Company,s recent announcement ... adjunctive therapy in adults with partial onset seizures. The ...
... A University of California, San Diego bioengineer is the ... Science that provides insights on the "stickiness of ... organisms hailing from all limbs of the tree of ... example, the researchers outlined similar strategies across biology for ...
Cached Biology Technology:Marinus Pharmaceuticals Raises $20 Million in Series B Financing 2Marinus Pharmaceuticals Raises $20 Million in Series B Financing 3Marinus Pharmaceuticals Raises $20 Million in Series B Financing 4Marinus Pharmaceuticals Raises $20 Million in Series B Financing 5Life sticks: UC San Diego bioengineer's sticky insights published in journal Science 2Life sticks: UC San Diego bioengineer's sticky insights published in journal Science 3Life sticks: UC San Diego bioengineer's sticky insights published in journal Science 4
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: